Literature DB >> 11222612

Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.

J Mogridge1, M Mourez, R J Collier.   

Abstract

Protective antigen (PA), a component of anthrax toxin, binds receptors on mammalian cells and is activated by a cell surface protease. The resulting active fragment, PA(63), forms ring-shaped heptamers, binds the enzymic moieties of the toxin, and translocates them to the cytosol. Of the four crystallographic domains of PA, domain 1 has been implicated in binding the enzymic moieties; domain 2 is involved in membrane insertion and oligomerization; and domain 4 binds receptor. To determine the function of domain 3, we developed a screen that allowed us to isolate random mutations that cause defects in the activity of PA. We identified several mutations in domain 3 that affect monomer-monomer interactions in the PA(63) heptamer, indicating that this may be the primary function of this domain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222612      PMCID: PMC95109          DOI: 10.1128/JB.183.6.2111-2116.2001

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  21 in total

1.  Human furin is a calcium-dependent serine endoprotease that recognizes the sequence Arg-X-X-Arg and efficiently cleaves anthrax toxin protective antigen.

Authors:  S S Molloy; P A Bresnahan; S H Leppla; K R Klimpel; G Thomas
Journal:  J Biol Chem       Date:  1992-08-15       Impact factor: 5.157

2.  Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.

Authors:  R O Blaustein; T M Koehler; R J Collier; A Finkelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

3.  Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha.

Authors:  R Pellizzari; C Guidi-Rontani; G Vitale; M Mock; C Montecucco
Journal:  FEBS Lett       Date:  1999-11-26       Impact factor: 4.124

4.  Anthrax protective antigen: prepore-to-pore conversion.

Authors:  C J Miller; J L Elliott; R J Collier
Journal:  Biochemistry       Date:  1999-08-10       Impact factor: 3.162

5.  pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen.

Authors:  J C Milne; R J Collier
Journal:  Mol Microbiol       Date:  1993-11       Impact factor: 3.501

6.  The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity.

Authors:  Y Singh; K R Klimpel; C P Quinn; V K Chaudhary; S H Leppla
Journal:  J Biol Chem       Date:  1991-08-15       Impact factor: 5.157

7.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

8.  Anthrax protective antigen forms oligomers during intoxication of mammalian cells.

Authors:  J C Milne; D Furlong; P C Hanna; J S Wall; R J Collier
Journal:  J Biol Chem       Date:  1994-08-12       Impact factor: 5.157

9.  Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin.

Authors:  V M Gordon; S H Leppla; E L Hewlett
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

10.  Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process.

Authors:  A M Friedlander
Journal:  J Biol Chem       Date:  1986-06-05       Impact factor: 5.157

View more
  31 in total

1.  The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.

Authors:  Jeremy Mogridge; Kristina Cunningham; D Borden Lacy; Michael Mourez; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

2.  Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.

Authors:  Kristina Cunningham; D Borden Lacy; Jeremy Mogridge; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-07       Impact factor: 11.205

3.  Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.

Authors:  D Borden Lacy; Darran J Wigelsworth; Roman A Melnyk; Stephen C Harrison; R John Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

4.  Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.

Authors:  E D Williamson; I Hodgson; N J Walker; A W Topping; M G Duchars; J M Mott; J Estep; C Lebutt; H C Flick-Smith; H E Jones; H Li; C P Quinn
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  Domain flexibility modulates the heterogeneous assembly mechanism of anthrax toxin protective antigen.

Authors:  Geoffrey K Feld; Alexander F Kintzer; Iok I Tang; Katie L Thoren; Bryan A Krantz
Journal:  J Mol Biol       Date:  2011-10-31       Impact factor: 5.469

6.  Receptor-specific requirements for anthrax toxin delivery into cells.

Authors:  G Jonah A Rainey; Darran J Wigelsworth; Patricia L Ryan; Heather M Scobie; R John Collier; John A T Young
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-01       Impact factor: 11.205

7.  Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.

Authors:  Ming Yan; Michael H Roehrl; Emre Basar; Julia Y Wang
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

8.  Cisplatin inhibition of anthrax lethal toxin.

Authors:  Mahtab Moayeri; Jason F Wiggins; Robin E Lindeman; Stephen H Leppla
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 9.  Membrane translocation by anthrax toxin.

Authors:  R John Collier
Journal:  Mol Aspects Med       Date:  2009-06-27

10.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.